Condition
MET Amplification
Total Trials
7
Recruiting
5
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 7 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
7Total
P 1 (2)
P 2 (5)
Trial Status
Recruiting5
Unknown2
Clinical Trials (7)
Showing 7 of 7 trials
NCT07322783Phase 2Recruiting
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
NCT03175224Phase 2Recruiting
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT04084717Phase 2Recruiting
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
NCT06109558Phase 1Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
NCT05800340Phase 2Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
NCT04292119Phase 1Unknown
Lorlatinib Combinations in Lung Cancer
NCT04647838Phase 2Unknown
Tepotinib in Solid Tumors Harboring MET Alterations
Showing all 7 trials